Trial · NCT01672853
Results by group21
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 21
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in MQC on Liver Biopsy at Week 96 | SIM 75 mg | -0.5 | Standard Deviation 5.78 | percentage of MQC | |
| Change From Baseline in MQC on Liver Biopsy at Week 96 | SIM 125 mg | 0.5 | Standard Deviation 6.94 | percentage of MQC | |
| Change From Baseline in MQC on Liver Biopsy at Week 96 | Placebo | 0.0 | Standard Deviation 4.76 | percentage of MQC | |
| Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event | SIM 75 mg | 5.1 | percentage of participants | ||
| Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event | SIM 125 mg | 7.8 | percentage of participants | ||
| Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event | Placebo | 10.3 | percentage of participants | ||
| Study Drug Exposure | SIM 75 mg | 92.0 | Standard Deviation 15.33 | weeks | |
| Study Drug Exposure | SIM 125 mg | 83.8 | Standard Deviation 26.12 | weeks | |
| Study Drug Exposure | Placebo | 87.4 | Standard Deviation 22.35 | weeks | |
| Percentage of Participants Experiencing Any Treatment-Emergent Laboratory Abnormality | SIM 75 mg | Grade 1 | 11.4 | percentage of participants | |
| Percentage of Participants Experiencing Any Treatment-Emergent Laboratory Abnormality | SIM 125 mg | Grade 1 | 16.9 | percentage of participants | |
| Percentage of Participants Experiencing Any Treatment-Emergent Laboratory Abnormality | Placebo | Grade 1 | 17.9 | percentage of participants | |
| Percentage of Participants Experiencing Any Treatment-Emergent Laboratory Abnormality | SIM 75 mg | Grade 2 | 26.6 | percentage of participants | |
| Percentage of Participants Experiencing Any Treatment-Emergent Laboratory Abnormality | SIM 125 mg | Grade 2 | 20.8 | percentage of participants | |
| Percentage of Participants Experiencing Any Treatment-Emergent Laboratory Abnormality | Placebo | Grade 2 | 25.6 | percentage of participants | |
| Percentage of Participants Experiencing Any Treatment-Emergent Laboratory Abnormality | SIM 75 mg | Grade 3 | 48.1 | percentage of participants | |
| Percentage of Participants Experiencing Any Treatment-Emergent Laboratory Abnormality | SIM 125 mg | Grade 3 | 46.8 | percentage of participants | |
| Percentage of Participants Experiencing Any Treatment-Emergent Laboratory Abnormality | Placebo | Grade 3 | 48.7 | percentage of participants | |
| Percentage of Participants Experiencing Any Treatment-Emergent Laboratory Abnormality | SIM 75 mg | Grade 4 | 11.4 | percentage of participants | |
| Percentage of Participants Experiencing Any Treatment-Emergent Laboratory Abnormality | SIM 125 mg | Grade 4 | 13.0 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01672853/results